Celsius Therapeutics, which has launched with series A capital, has become the latest Third Rock-launched company to be backed by GV.

The Cambridge spinout has raised $15m in series A funding from investors including Cambridge Enterprise and Parkwalk Advisors.

NUS spinout MediSix has obtained $20m from investors including Osage University Partners to commercialise research into leukaemia and lymphoma treatments.

Beam has emerged out of Harvard University with $87m in series A funding to commercialise gene editing technology, with additional research licensed from Broad Institute and Editas Medicine.

Axiom Energy, backed by the Stanford-StartX Fund, has received series A capital from a consortium including corporates Great Plains Energy and Shell.

The UCSF oncological therapeutics spinout will move from California to Connecticut following a leading investment from state-owned Connecticut Innovations.

Based on research at Johns Hopkins University, Escient Pharmaceuticals is developing treatments for serious but unserved medical needs.

The University of Leicester spinout will put the funding towards recruitment and moving its synthetic antibody operation into larger premises.

The autonomous vision technology developer raised the cash in a GM Ventures-led round that included fellow corporate venturing unit Intact Ventures.